These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 1962596)
21. The estrogenic and antiestrogenic activities of droloxifene in human breast cancers. Kawamura I; Mizota T; Lacey E; Tanaka Y; Manda T; Shimomura K; Kohsaka M Jpn J Pharmacol; 1993 Sep; 63(1):27-34. PubMed ID: 8271528 [TBL] [Abstract][Full Text] [Related]
22. Phase I study of the tolerance and pharmacokinetics of toremifene in patients with cancer. Kohler PC; Hamm JT; Wiebe VJ; DeGregorio MW; Shemano I; Tormey DC Breast Cancer Res Treat; 1990 Aug; 16 Suppl():S19-26. PubMed ID: 2149280 [TBL] [Abstract][Full Text] [Related]
23. [The results of a comparative clinical study of the antiestrogenic preparations toremifene and tamoxifen in locally advanced and disseminated breast cancer]. Konstantinova MM; Gershanovich MA Vopr Onkol; 1990; 36(10):1182-6. PubMed ID: 2147527 [TBL] [Abstract][Full Text] [Related]
24. Induction of transforming growth factor beta by the antiestrogens droloxifene, tamoxifen, and toremifene in MCF-7 cells. Knabbe C; Zugmaier G; Schmahl M; Dietel M; Lippman ME; Dickson RB Am J Clin Oncol; 1991; 14 Suppl 2():S15-20. PubMed ID: 1835818 [TBL] [Abstract][Full Text] [Related]
25. Droloxifene, a new antiestrogen. Hormonal influences in postmenopausal breast cancer patients. Kvinnsland S Am J Clin Oncol; 1991; 14 Suppl 2():S46-51. PubMed ID: 1962597 [TBL] [Abstract][Full Text] [Related]
26. Phase II clinical study of toremifene in patients with metastatic breast cancer. Preliminary communication. Modig H; Borgström S; Nilsson I; Westman G J Steroid Biochem; 1990 Jun; 36(3):235-6. PubMed ID: 2142242 [TBL] [Abstract][Full Text] [Related]
27. Steroid hormone levels in patients with advanced breast cancer during therapy with droloxifene: a pilot study. Dalski J; Görlich M Tumori; 1996; 82(1):45-7. PubMed ID: 8623503 [TBL] [Abstract][Full Text] [Related]
28. Anti-implantation effect of droloxifene in rats and its relationship with anti-estrogenic activity. Huang Y; Shen Y; Feng Y; Cao L; Leng Y Acta Pharmacol Sin; 2005 Oct; 26(10):1243-7. PubMed ID: 16174441 [TBL] [Abstract][Full Text] [Related]
29. Pharmacologic and biologic properties of droloxifene, a new antiestrogen. Eppenberger U; Wosikowski K; Küng W Am J Clin Oncol; 1991; 14 Suppl 2():S5-14. PubMed ID: 1962598 [TBL] [Abstract][Full Text] [Related]
30. Neoadjuvant percutaneous 4-hydroxytamoxifen decreases breast tumoral cell proliferation: a prospective controlled randomized study comparing three doses of 4-hydroxytamoxifen gel to oral tamoxifen. Rouanet P; Linares-Cruz G; Dravet F; Poujol S; Gourgou S; Simony-Lafontaine J; Grenier J; Kramar A; Girault J; Le Nestour E; Maudelonde T J Clin Oncol; 2005 May; 23(13):2980-7. PubMed ID: 15860853 [TBL] [Abstract][Full Text] [Related]
31. Influence of droloxifene on plasma levels of insulin-like growth factor (IGF)-I, Pro-IGF-IIE, insulin-like growth factor binding protein (IGFBP)-1 and IGFBP-3 in breast cancer patients. Helle SI; Anker GB; Tally M; Hall K; Lønning PE J Steroid Biochem Mol Biol; 1996 Feb; 57(3-4):167-71. PubMed ID: 8645625 [TBL] [Abstract][Full Text] [Related]
32. Phase III studies of toremifene in metastatic breast cancer. Pyrhönen SO Breast Cancer Res Treat; 1990 Aug; 16 Suppl():S41-6. PubMed ID: 2149285 [TBL] [Abstract][Full Text] [Related]
33. Phase I study of percutaneous 4-hydroxy-tamoxifen with analyses of 4-hydroxy-tamoxifen concentrations in breast cancer and normal breast tissue. Pujol H; Girault J; Rouanet P; Fournier S; Grenier J; Simony J; Fourtillan JB; Pujol JL Cancer Chemother Pharmacol; 1995; 36(6):493-8. PubMed ID: 7554041 [TBL] [Abstract][Full Text] [Related]
34. Effects of high dose raloxifene in selected patients with advanced breast carcinoma. Gradishar W; Glusman J; Lu Y; Vogel C; Cohen FJ; Sledge GW Cancer; 2000 May; 88(9):2047-53. PubMed ID: 10813716 [TBL] [Abstract][Full Text] [Related]
35. Phase II clinical study of high-dose toremifene in patients with advanced breast cancer. Modig H; Borgström S; Nilsson I; Westman G J Steroid Biochem; 1990 Jun; 36(3):237-8. PubMed ID: 2142243 [TBL] [Abstract][Full Text] [Related]
36. [Breast cancer--tamoxifen and tamoxifen analogues for the treatment of breast cancer]. Iino Y; Morishita Y Nihon Rinsho; 1994 Mar; 52(3):797-803. PubMed ID: 8164385 [TBL] [Abstract][Full Text] [Related]
37. Cardiovascular effects of droloxifene, a new selective estrogen receptor modulator, in healthy postmenopausal women. Herrington DM; Pusser BE; Riley WA; Thuren TY; Brosnihan KB; Brinton EA; MacLean DB Arterioscler Thromb Vasc Biol; 2000 Jun; 20(6):1606-12. PubMed ID: 10845879 [TBL] [Abstract][Full Text] [Related]
38. [Status of estrogen receptor affects the drug sensitivity of drug-resistant MCF-7/Adr human breast cancer cells to droloxifene and Adriamycin]. Gao HD; Sun JZ; Bi DS; Ma R Ai Zheng; 2003 Apr; 22(4):376-9. PubMed ID: 12703992 [TBL] [Abstract][Full Text] [Related]
39. Endocrine management of breast cancer. Schneider PG; Jackisch C; Brandt B Int J Fertil Menopausal Stud; 1994; 39 Suppl 2():115-27. PubMed ID: 7874188 [TBL] [Abstract][Full Text] [Related]
40. Tamoxifen vs Tamoxifen plus 13-cis-retinoic acid vs Tamoxifen plus Interferon alpha-2a as first-line endocrine treatments in advanced breast cancer: updated results of a phase II, prospective, randomised multicentre trial. Chiesa MD; Passalacqua R; Michiara M; Franciosi V; Di Costanzo F; Bisagni G; Camisa R; Buti S; Tomasello G; Cocconi G; Acta Biomed; 2007 Dec; 78(3):204-9. PubMed ID: 18330080 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]